Nationwide Fund Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nationwide Fund Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,579	Closed	-$273K	–	2250
2017 Q3	$273K	Sell	4,579 -230	-5%	-$13.9K	﹤0.01%	2482
2017 Q2	$379K	Sell	4,809 -7,703	-62%	-$630K	﹤0.01%	2321
2017 Q1	$1.04M	Sell	12,512 -7,434	-37%	-$553K	﹤0.01%	1730
2016 Q4	$1.58M	Sell	19,946 -1,185	-6%	-$86.1K	0.01%	1526
2016 Q3	$1.48M	Sell	21,131 -500	-2%	-$27.7K	0.01%	1551
2016 Q2	$839K	Buy	21,631 +4,923	+29%	+$205K	﹤0.01%	1851
2016 Q1	$677K	Sell	16,708 -4,104	-20%	-$260K	﹤0.01%	1922
2015 Q4	$1.84M	Buy	20,812 +4,426	+27%	+$349K	0.01%	1400
2015 Q3	$1.21M	Buy	16,386 +222	+1%	+$18.5K	0.01%	1626
2015 Q2	$1.31M	Buy	+16,164	New	+$1.05M	0.01%	1702
2014 Q2	–	Sell	-10,834	Closed	-$138K	–	3391
2014 Q1	$138K	Buy	+10,834	New	+$147K	﹤0.01%	2639

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nationwide Fund Advisors's EGRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 4,579 shares — an estimated $273K sold.

Nationwide Fund Advisors first reported a position in EGRX in Q1 2014 and held it in 11 quarters. The position peaked at $1.84M in Q4 2015. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

Nationwide Fund Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 4,579 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $273K.
Nationwide Fund Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
Nationwide Fund Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.84M in Q4 2015.
170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.